Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry.

Competing Interests: Dr Silverberg has received honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena, Amgen, AOBiome, Arcutis, Arena, Asana, Aslan, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Celgene, Connect BioPharma, Dermavant, Dermira, DermTech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, Union, and UpToDate; has served as a speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; and has received grants (paid to the institution) from Galderma, 10.13039/100017655Incyte, and 10.13039/100004319Pfizer. Author Cronin and Drs Jones and Dave were employees of CorEvitas, LLC at the time of this work. Dr McLean is an employee of CorEvitas, LLC. Dr Greenberg is an employee of CorEvitas, LLC. Dr Strober has received honoraria as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Connect BioPharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Immunic Therapeutics, Janssen, Leo Pharma, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB, Ventyxbio, and vTv Therapeutics; has served as a speaker for AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme; coscientific director (consulting fee) for CorEvitas’ (Corrona) Psoriasis Registry; and investigator for AbbVie, Cara, CorEvitas’ (Corrona) Psoriasis Registry, Dermavant, Dermira, and Novartis. Dr Bieber has served as a speaker and/or consultant, and/or investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiome, Arena, Aristea, Asana Biosciences, ASLAN pharma, Bayer Health, BioVersys, Boehringer Ingelheim, Bristol Myers Squibb, Connect Pharma, Daiichi Sankyo, Dermavant, DICE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, MSD, Medac, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32 Bio, RAPT, Sanofi/Regeneron, UCB, and Union Therapeutics; and is the founder and chairman of the board of the nonprofit biotech “Davos Biosciences.” Dr Gooderham has served as an investigator, speaker, and/or adviser for AbbVie, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, MoonLake, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, and Ventyx. Dr Paller has served as an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, and UCB; has served as a consultant for Aegerion Pharma, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, TWI Biotechnology, and UCB; and as a data safety monitoring board member for AbbVie, Abeona, Catawba, Galderma, and InMed. Dr Simpson has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Aslan Pharma, Benevolent AI Bio Limited “BAI,” BiomX Ltd, Bluefin Biomedicine Inc, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, LLC (CA), Coronado, Dermira, Eli Lilly, Evidera, Excerpta Medica, Galderma, GlaxoSmithKline, Forte Bio RX, Incyte Dermatologics, Janssen, Kyowa Kirin Pharmaceutical Development, Leo Pharm, Medscape LLC, Merck, Novartis, Ortho Galderma, Pfizer, Physicians World LLC, Pierre Fabre Dermo Cosmetique, Regeneron, Roivant, Sanofi-Genzyme, SPARC India, Trevi Therapeutics, WebMD, and Valeant; has served as a speaker for AbbVie, Leo, Eli Lilly, Medscape, Pfizer, Regeneron, Sanofi-Genzyme; has received advisory or steering committee fee from Arena Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin Pharmaceutical Development, Leo, Pfizer, Regeneron and Sanofi-Genzyme; has received grants or contracts from AbbVie, Amgen, Arcutis, Aslan, Celgene, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Kymab, Kyowa Hakko Kirin, Leo Pharmaceuticals, Merck, Novartis, Pfizer, Regeneron, Sanofi, and TARGET-DERM; and has been a PI for CorEvitas (paid to the institution).